Charles River Labs Intl Stock
Price
Target price
€199.30
€199.30
-0.450%
-0.9
-0.450%
€248.57
09:48 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
Charles River Labs Intl shows a slight decrease today, losing -€0.900 (-0.450%) compared to yesterday.
Charles River Labs Intl is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
With a target price of 248 € there is a positive potential of 24.44% for Charles River Labs Intl compared to the current price of 199.3 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | -0.450% | -1.815% | -5.699% | 10.638% | -6.009% | -25.299% | - |
| Ironwood Pharmaceuticals | -1.800% | -6.034% | -26.351% | -46.040% | -46.569% | -44.388% | - |
| Novocure Ltd | -1.550% | 5.435% | 80.694% | -68.865% | 49.492% | -86.241% | - |
| Iovance Biotherapeutics Inc. | -0.200% | -2.040% | -15.122% | 31.330% | 18.110% | -40.117% | - |
Comments
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at Robert W. Baird from $282.00 to $270.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $260.00 to $265.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at UBS Group AG from $270.00 to $290.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
News
Charles River Laboratories Announces First-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024